U.S. FDA grants Orphan Drug Designation to imsidolimab for treatment of generalised pustular psoriasis (GPP)

This anti-interleukin-36 receptor antibody is being evaluated in GALLOP Phase 2 trial in patients with this chronic, life-threatening, rare disease with no currently approved therapies, and for which currently approved psoriasis treatments have not demonstrated clear efficacy.


Biospace Inc.